

**Kala Pharmaceuticals to Present at the Association for Research in Vision and Ophthalmology  
2015 Annual Meeting**

---

WALTHAM, Mass., May 1, 2015 – [Kala Pharmaceuticals, Inc.](#) (Kala), a developer of innovative ophthalmic products based on its proprietary mucus-penetrating particle (MPP) technology, announced that a poster has been selected for presentation at the [Association for Research in Vision and Ophthalmology \(ARVO\) 2015 Annual Meeting](#) taking place May 3-7, 2015, in Denver, CO. Kala will present new preclinical data for K106, a novel, topical Receptor Tyrosine Kinase inhibitor (RTKi) candidate designed to potently and selectively block VEGF signaling. Information for the poster session is as follows:

- **Topical Delivery of a Novel Receptor Tyrosine Kinase Inhibitor (RTKi) via Mucus-Penetrating Particles**

Poster #: 2279 - B0184

Date/Time: Monday, May 4, 2015 from 2:45 PM to 5:30 PM MT

Session #/Title: 281, Novel targets and therapies

The [ARVO Annual Meeting](#) is the largest gathering of eye and vision researchers in the world and provides a first look at science that could translate into clinical practice in the near future and potentially transform diagnostics and treatments for blinding eye conditions.

**About Kala Pharmaceuticals, Inc.**

Kala is a clinical stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Beyond ophthalmology, Kala's MPP technology has potential applications in women's reproductive health, respiratory and gastrointestinal diseases, and other indications.

Kala was founded by leaders in the fields of nanomedicine and biopharmaceutical engineering, and is backed by leading life sciences investors including Crown Venture Fund, Lux Capital, Polaris Partners, Third Rock Ventures and Ysios Capital. For more information, please visit Kala's website at [www.kalarx.com](http://www.kalarx.com).

**Contact:**

Kari Watson

(781) 235-3060

[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)

or Hunter Marshall

(650) 342-1000

[hmarshall@macbiocom.com](mailto:hmarshall@macbiocom.com)

MacDougall Biomedical Communications

###